Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit i
AssigneesChildren's Medical Center Corporation, Alseres Pharmaceuticals, Inc.
InventorsRichard M. Thorn, Marc E. Lanser, Marsha A. Moses, Dmitri G. Wiederschain
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.
Claims3
An isolated peptide consisting of a region of troponin subunit I having amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).
A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder in a mammal which comprises an effective amount of a peptide which is at least 80% homologous with amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).
A method of inhibiting angiogenesis associated with a disease or disorder in a mammal, comprising administering an effective amount of a peptide which is at least 80% homologous with amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).
Dependencies are inferred from the claim text.